$Rocket Lab USA, Inc.(RKLB)$ I don't have the exact numbers, but RKLB went from near $100 down to around $60, then back up to about $150. This dip seems to indicate a move toward $225.
My top picks across sectors right now with three-year targets: Defense: EOS.AX - target $35 (next-gen electro-optical systems plus defense optics cycle expansion) Healthcare: $Oscar Health, Inc.(OSCR)$ - target $75 (health insurance tech platform, utilization, and pricing cycle upside) Space: $Rocket Lab USA, Inc.(RKLB)$ - target $380 (launch cadence scaling and space infrastructure commercialization phase) Energy: $Bloom Energy Corp(BE)$ - target $375 (fuel cell, distributed power, and data center energy demand tailwind) Physical AI: $XPeng Inc.(XPEV)$ - target $130 (autonomy, EV, and robotics conv
NASA has selected $Rocket Lab USA, Inc.(RKLB)$ to launch two Sun and Earth science missions. NASA has chosen Rocket Lab to provide launch services for its PolSIR (Polarized Submillimeter Ice-cloud Radiometer) and TSIS-2 (Total and Spectral Solar Irradiance Sensor-2) missions. These two selections are part of NASA's VADR (Venture-Class Acquisition of Dedicated and Rideshare) launch services contract. This contract allows the agency to award fixed-price, indefinite-delivery/indefinite-quantity launch service task orders during VADR's 10-year ordering period, with a maximum total contract value of $300 million.
$Rocket Lab USA, Inc.(RKLB)$ Governments are increasingly looking for companies that can handle the full mission solution: building satellites, launching them, operating them, and responding quickly when national security demands it. The winners might not be those with the biggest rockets, but those offering complete packages. That's why Rocket Lab's (RKLB) latest Victus Haze mission could be more significant than the launch itself. For investors, it signals that RKLB is evolving into something much larger than just a small launch company.
$Rocket Lab USA, Inc.(RKLB)$ Hoping they'll announce the completion of the $3B project soon, that might stop the bleeding. It seems like all the other good news and launches post-IPO haven't really moved the needle for SPCX. Still love the stock and remain bullish, just feeling a bit down in the short term.